Japan's Ministry of Health, Labor and Welfare has raised its fiscal year 2006 draft budget 2.6% to 21,476.0 billion yen ($180.25 billion) compared to a year ago.
The disease management budget earmarked 22.7 billion yen for cancer, including 1.5 billion yen from a supplementary budget for fiscal 2006. The total figure represents a 51% increase compared to a year ago. The cancer funding was allocated to promoting the prevention and early detection of cancer (3.0 billion yen); standardizing of cancer treatment, educating cancer experts and the establishment of systems for collecting and providing information on cancer treatment (9.0 billion yen); and, promotion of cancer R&D of new medical technology for the disease (8.7 billion yen).
In the life-style diseases and preventative care areas, 142.2 billion yen was allocated. Among them, 107.4 billion yen and 9.8 billion yen were earmarked for preventative care and promoting countermeasures against metabolic syndrome, respectively. In addition, 198.4 billion yen was allocated for infectious diseases management including avian influenza, new and re-emerging infectious diseases, hepatitis and HIV/AIDS. Outlays for pharmaceuticals and medical device safety and fast-track provision will fall 6.1% to 10.8 billion yen, including 560.0 million yen for promoting the safe use of drugs, collecting data on the safety of new drugs in post-marketing studies and ensuring the supply of safe blood preparations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze